GSK report:. The growth in Pharmaceuticals benefited from the governmentstockpiling ofRelenza, with sales more than doublingmaybe because it is cheaper ?
PV1 Provaris tells ASX non-binding MOUs are still material to share prices in somewhat fiery compliance response